Table 3

Potential opportunities for (a) lives saved and (b) non-fatal events prevented and components of these benefits (with sensitivity analysis) through better application of treatments and possible innovations

Deaths per 10 000Range in sensitivity analysisRecurrent MI or stroke per 10 000Range in sensitivity analysis
Total events: STEMI232 to 6021324 to 527
Delayed presentation61 to 136014 to 127
Fibrinolysis rather than PPCI10 to 5120 to 45
Delayed PPCI30 to 10380 to 92
Delayed fibrinolysis10 to 3111 to 26
No reperfusion73 to 178325 to 161
Delayed invasive management00 to 120 to 4
No invasive management10 to 750 to 27
Total Events: NSTEMI430 to 177550 to183
Delay invasive management40 to 1030 to 8
No invasive management160 to 87110 to 67
No GP210 to 59400 to 96
Total events: secondary prevention treatments10427 to 26619161 to 605
    Lack of prescription4616 to 10112136 to 229
    Non-adherence5811 to 1656924 to 376
Putative novel therapyOptimal*All†OptimalAll
10% Reduction134496
20% Reduction3679192
30% Reduction410113288
  • *Optimal—for patients with STEMI: reperfusion, early invasive management and GP IIb/IIIa inhibition; for patients with NSTEMI: early invasive management and GP IIb/IIIa inhibition; for secondary prevention: four or five guideline recommended treatments at discharge and adherent at 6 months; †All–a benefit that applies to the entire population.

  • GP, glycoprotein; MI, myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; PPCI, primary percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.